Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACR | P10323 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 8/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28592609 | 0.88 | ALDH1A1 (0.58) | ACRALDH1A1MAPTLMNANPC1 | |
| SCHEMBL29197994 | 0.88 | ACR (0.60) | ACRALDH1A1MAPTL3MBTL1LMNA | |
| SCHEMBL2967105 | 0.87 | TP53 (0.57) | ACRALDH1A1MAPTL3MBTL1LMNA | |
| SCHEMBL21523600 | 0.87 | ACR (0.56) | ACRALDH1A1MAPTL3MBTL1LMNA | |
| SCHEMBL1686391 | 0.85 | TP53 (0.62) | ACRMAPTLMNANPC1RAB9A | |
| SCHEMBL27237216 | 0.85 | ACR (0.58) | ACRALDH1A1MAPTL3MBTL1LMNA | |
| SCHEMBL1686347 | 0.85 | POLB (0.66) | ACRALDH1A1MAPTL3MBTL1HPGD | |
| SCHEMBL1686476 | 0.85 | MAPT (0.72) | ACRALDH1A1MAPTL3MBTL1LMNA | |
| SCHEMBL28388709 | 0.85 | SMPD1 (0.68) | ACRMAPTL3MBTL1LMNAMEN1 | |
| SCHEMBL5620054 | 0.85 | SMN1; SMN2 (0.56) | ACRALDH1A1MAPTL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208923-A1 | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION | JNANA THERAPEUTICS INC. | 2024-06-27 | — | — | US | disclosed |
| WO-2024081864-A1 | INHIBITORS OF NT5C2 AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2024-04-18 | — | — | WO | disclosed |
| CN-117417334-A | Azole derivative containing isoxazole structure, and preparation method and application thereof | 沈阳药科大学 | 2024-01-19 | — | — | CN | disclosed |
| US-11787783-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-10-17 | — | — | US | disclosed |
| US-11787783-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-10-17 | — | — | US | disclosed |
| US-11739064-B2 | HDAC inhibitors and therapeutic methods using the same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739064-B2 | HDAC inhibitors and therapeutic methods using the same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-08-29 | — | — | US | disclosed |
| US-11718609-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-08-08 | — | — | US | disclosed |
| US-11718609-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-08-08 | — | — | US | disclosed |
| CN-110156708-B | Substituted heterocyclic compound containing acylhydrazone skeleton and preparation method and application thereof | 中国药科大学 | 2022-08-09 | — | — | CN | disclosed |
| EP-1077957-A1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Chemical Industries, Ltd. (JP) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058510-A1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-11-18 | — | — | WO | disclosed |
| US-5602160-A | MUSCLE RELAXANT | MITSUI TOATSU CHEMICALS INCORPORATED (JP) | 1997-02-11 | — | — | US | disclosed |
| US-5498619-A | MUSCLE RELAXANTS, POLLAKIUREA CURING AGENTS AND MUSCLE SPASMS | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1996-03-12 | — | — | US | disclosed |
| EP-0414391-B1 | Aminoketone derivatives and use thereof | MITSUI TOATSU CHEMICALS (JP) | 1995-03-15 | — | — | EP | disclosed |
| US-5338857-A | Muscle relaxant | MITSUI TOATSU CHEMICALS INCORPORATED (JP) | 1994-08-16 | — | — | US | disclosed |
| US-5041567-A | Human and veterianary medicine; veneral diseases respiratory diseases, bovine mastitis | BEECHAM GROUP PLC (GB) | 1991-08-20 | — | — | US | disclosed |
| EP-0414391-A2 | Aminoketone derivatives and use thereof | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1991-02-27 | — | — | EP | disclosed |
| US-4812470-A | Antibacterial monic acid derivatives | BEECHAM GROUP P.L.C. (GB) | 1989-03-14 | — | — | US | disclosed |
| EP-0087953-B1 | ANTIBACTERIAL 1-NORMON-2-YL-HETEROCYCLIC COMPOUNDS | BEECHAM GROUP PLC (GB) | 1988-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208923-A1 | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION | SLC18A2, SLC6A19, SLC1A1 | ACR 4822/4885ALDH1A1 1257/4885MAPT 710/4885 |
| US-11787783-B2 | Heparanase inhibitors and use thereof | HPSE, HEXD, ENGASE | ACR 1985/4885ALDH1A1 1394/4885MAPT 2923/4885 |
| US-11739064-B2 | HDAC inhibitors and therapeutic methods using the same | HDAC1, HDAC9, HDAC8 | ACR 1311/4885ALDH1A1 1366/4885MAPT 127/4885 |
| US-11718609-B2 | Heparanase inhibitors and use thereof | HPSE, HEXD, ENGASE | ACR 1724/4885ALDH1A1 2194/4885MAPT 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.